Related Experiment Video
Updated: Aug 8, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability
M R Rezvany1, M Jeddi-Tehrani, P Biberfeld
1Immune and Gene Therapy Laboratory CCK, Karolinska Hospital, Stockholm, Sweden.
Insights
Dendritic cells (DCs) from chronic lymphocytic leukemia (CLL) patients show normal function for immunotherapy. Despite some molecular differences, CLL DCs can present tumor antigens, suggesting their potential in therapeutic vaccination strategies.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Background:
- Dendritic cells (DCs) are crucial for immunotherapy and vaccine development.
- Chronic lymphocytic leukemia (CLL) is a B-cell malignancy where DC function may be altered.
- Understanding DC capabilities in CLL is vital for developing effective cancer treatments.
Purpose of the Study:
- To analyze the functional capacity of dendritic cells (DCs) generated in vitro from CLL patients.
- To compare CLL-derived DCs with those from healthy donors for potential immunotherapy applications.
- To investigate molecular and functional differences in DCs from CLL patients.
Main Methods:
- Generation of DCs in vitro from CD14(+) cells using GM-CSF, IL-4, and TNF-alpha.
- Phenotypic analysis of DC populations using flow cytometry (CD11c, CD123, CD83, MHC class II, CD14, CD54, CD80, CD86, MHC class I).
- Gene expression analysis (real-time PCR) for cytokines (IL-10, IL-1beta, IL-12p35, IL-4, TNF-alpha, IFN-gamma) and functional assays (mixed leukocyte reaction, recall antigen presentation).
Main Results:
- Two distinct DC populations (CD11c+ and CD123+) were identified in both CLL patients and controls.
- Most DCs exhibited a mature phenotype (CD83+, MHC class II+) with characteristic morphology.
- CLL DCs showed higher expression of CD80 and MHC class I, and increased IL-10 gene expression compared to controls.
- Despite cytokine profile differences, CLL DCs demonstrated similar mixed leukocyte reaction and recall antigen presentation capabilities as control DCs.
Conclusions:
- Dendritic cells (DCs) from CLL patients exhibit normal functional capacity for antigen presentation.
- CLL DCs may serve as effective antigen-presenting cells in therapeutic vaccination strategies for cancer.
- Observed molecular alterations in CLL DCs might indicate in vivo pre-activation, potentially influencing CLL pathobiology.
Abstract:
Dendritic cells (DC) are attractive candidates for use in vaccine-based immunotherapy. We have analysed the functional capability of DC generated in vitro from blood CD14(+) cells of chronic lymphocytic leukaemia (CLL) patients and healthy donors by culturing for 10 d with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 4 (IL-4) and tumour necrosis factor-alpha (TNF-alpha). Two distinct DC populations were identified in patients as well as in controls. The majority of DC expressed CD11c and a minority also CD123. Most of the DC generated from both patients and controls exhibited a mature phenotype indicated by CD83 and major histocompatibility complex (MHC) class II expression, as well as by a characteristic morphology. Less than 1% of DC exhibited CD14. CLL DC had a similar expression of accessory molecules (CD54, CD80 and CD86) as control DC. The mean fluorescence intensity of CD80 and MHC class I molecules was significantly higher on CLL DC than on control DC (P < 0.05). At the gene level (real-time polymerase chain reaction) the expression of IL-10 was higher in CLL (P = 0.028) than in control DC. IL-1 beta and IL-12p(35) transcripts were also more abundant in CLL than in control DC but did not reach statistical significance. The expression of IL-4 and TNF-alpha was similar to that of control DC. The interferon gamma (IFN-gamma) gene expression level in CLL DC was decreased compared with control DC. DC of CLL patients had a similar capacity to stimulate in mixed leucocyte reaction as well as to present a recall antigen (PPD) as control DC. Thus, DC of CLL patients seem to have a normal function and may serve as antigen preserving cells for presentation of tumour antigens in a therapeutic vaccination approach. The mechanisms behind the observed increase in some surface molecules and the abnormal cytokine profile of CLL DC is not clear but might indicate pre-activation of DC in vivo, which may have a regulatory role in the pathobiology of CLL.
More Related Videos
Related Concept Videos
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
01:23Cells of the Adaptive Immune Response